The outcome of TLR4 inhibition following acute ischemic injury to the kidney may be dependent on the context and cellular origin of TLR4 activation and further work is needed to clarify the benefit of TLR inhibition on the chronic outcomes of ischemic AKI. The gene discussed is TLR4; the disease is acute kidney injury.